Takeda (TAK) announced that the EMA has approved an additional two mL pre-filled pen option for Takhzyro for subcutaneous administration in ...

Takeda—the 21-year-old Japanese golfer with great bloodlines—turned a two-shot lead after 54 holes into a six-shot lead five holes into her final round. Takeda fired an 8-under 64 to win in dominant ...

Now that Takeda has won, the LPGA will take two weeks off before resuming in Arizona for the Ford Championship at Whirlwind Golf Club.

Takeda’s (NYSE: TAK) (TSE:4502) plasma-derived therapies (PDT) business, led by Giles Platford, president of Takeda’s Plasma-Derived Therapies Business Unit and chair of the Plasma Protein ...

Takeda has bolstered its near-term pipeline in rare haematological disorders by licensing rights to a polycythaemia vera (PV) treatment being developed by Protagonist Therapeutics. The Japanese ...

On Monday, Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the Phase 3 VERIFY study of rusfertide for polycythemia vera.

January 30, 2025 Drugmaker Takeda's CEO Weber to step down, raises profit forecast Takeda Pharmaceutical said on Thursday its CEO Christophe Weber will retire after more than a decade at the helm ...

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers ...

Three years after it was formed as a spinout of Japanese drugmaker Takeda, Phathom Pharmaceuticals has racked up its first FDA approvals, and claimed a sizeable $260 million in new financing to ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...